Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI362 in Mild to Moderate Hypertension Complicated by Overweight/Obesity
NCT07469800Phase 3Recruiting
- Sponsor
- Innovent Biologics
- Start
- Apr 2026
- Primary completion
- Aug 2026
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of mazdutide in hypertension (HTN), obesity, sponsored by Innovent Biologics. Started Apr 2026; status: recruiting.
02
Drugs
mazdutide
03
Conditions
hypertension (HTN)obesity
Beyond the preview
Go deeper on NCT07469800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07469800.